Ensem Therapeutics To Present Preclinical Data for Potential Best-in-Class Oral CDK2 Inhibitor at San Antonio Breast Cancer Symposium

Pfizer’s Tukysa (tucatinib) has enhanced patient outcomes when used as a maintenance therapy during a late-stage trial in breast cancer.

Telomir Pharmaceuticals, Inc., a $54 million market cap biotech company whose stock has declined 11% in the past week

60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study

One in three people with type one diabetes will develop kidney damage during their lifetime, which can develop silently over many years, often going undetected until it becomes severe.